BHI Team Members

Quan Nguyen is a Partner at Nguyen Tarbet Intellectual Property Law, representing inventors and organizations with impactful, cutting-edge technologies. Quan has a great passion for the process of commercializing new inventions. He works closely with his clients to build winning patent portfolios and helps identify strategic partners, screen for potential business deals, and analyze market opportunities. Quan is also an active member of the Tech Coast Angels (TCA), Desert Angels, and Life Science Angels, where he leads a number of investment deals. As a seasoned patent attorney, Quan concentrates his practice in patent procurement, opinion work (patentability and freedom to operate analysis), and intellectual property management of inventions in biotechnology, chemistry, medical devices, microfluidics, bioinformatics, and artificial intelligence. His clients include publicly traded companies, major corporations, universities, investors, and entrepreneurs. Prior to founding Nguyen Tarbet LLC, Quan was a Partner at Cozen O’Connor, an international law firm based in Philadelphia. Earlier in his career, Quan also worked in-house as an Assistant Director of Patents at Ionis Pharmaceuticals in San Diego, a leader in RNA-targeted therapeutics. Quan firmly believes in public service and works tirelessly to advance innovation and entrepreneurship. He is an active Member of the College of Science Dean’s Board of Advisors (University of Arizona), School of Pharmacy and Pharmaceutical Sciences Dean's Leadership Council (University of California, Irvine) and Beall Applied Innovation (University of California Irvine), where he leads various university initiatives to promote innovation through industry partnerships. As Chairman Emeritus of the Advisory Board of the Chemistry and BioChemistry Board of Advisors (University of Arizona), he helped the department develop strategic industry relationships to advance faculty research. Quan regularly speaks at seminars about innovation, technology investments, and trends in patent law.

Jon earned his doctorate in biology from Wake Forest University, specializing in neuroscience and the molecular mechanisms that underlie behavior. His early academic journey, which includes bachelor's and master's degrees in biology, focused on epigenetics and oncology. Jon’s experience spans academia and industry, including work as a patent engineer where he contributed to several patent applications. Jon has been a member of BioHealth Innovation since 2023, and now serves as Manager of Client Engagement, leading the Analyst team, assisting with commercialization and pitch coaching, as well as spearheading grant writing projects. With over 7 years of grant writing experience, Jon leverages his diverse background to guide clients through the process of obtaining non-dilutive funding and commercialization.

Dr. Kuldeep Neote is a seasoned biotechnology executive and venture capital professional with over 25 years of experience in external innovation, business development, and strategic partnerships across the life sciences industry. His career encompasses roles at leading pharmaceutical companies, innovative biotech ventures, and investment organizations, with particular expertise in immunology, oncology, and gene therapy development.

Deanne Randolph has a long record of success in strategic marketing for leading biotech, pharmaceutical, and consumer-driven healthcare brands. From early development through launch, Deanne has led multiple US, European, and global initiatives along with several major pharmaceutical and biotechnology product launches. Deanne’s ability to integrate professional, payer, and patient needs to identify growth-driving market strategies is particularly relevant in today’s competitive healthcare environment. She provides Sante Group clients expertise in strategic pre-launch planning, positioning, and targeting; life cycle management and clinical development strategy; global branding; medical education; and direct-to-consumer marketing. Deanne has worked in both primary and secondary care across a broad range of therapeutic areas including immunology, oncology, rheumatology, neurology, pain and rare diseases. Prior to consulting, Deanne held brand management and commercial development positions at Pfizer, Johnson & Johnson, and Bayer. She holds both an MBA and a BA from Wake Forest University.

John P. Reinhart is an accomplished C-suite executive and serial entrepreneur who specializes in Longevity Economy innovation, with nearly two decades of recognition for transformative contributions to healthcare and aging services. As a visionary leader in the intersection of technology, healthcare, and demographic change, he has co-founded multiple ventures and led organizations that address the evolving needs of America's aging population while creating scalable business solutions.

Maureen Richard is an accomplished medical device software professional with extensive expertise in providing software development lifecycle processes, system engineering, and documentation services to medical device startups and established companies. Based in Longmont, Colorado, she specializes in ensuring compliance with IEC 62304 and FDA regulations in regulated healthcare environments. Maureen holds a Master of Science in Medical Informatics from Northwestern University, Chicago, a Bachelor of Arts in Computer Science from the University of Texas, Austin, and a Bachelor of Science in Microbiology from Texas A&M University, College Station. This unique combination of technical, medical, and scientific education provides her with a comprehensive understanding of the intersection between healthcare technology and regulatory requirements.

Dr. Loleta Robinson is the President & CEO of Fortis Industries, LLC and a physician entrepreneur and healthcare investment strategist. She is known for her ability to bridge clinical insight with business acumen—advancing innovation, guiding commercialization strategies, and aligning cutting-edge medical solutions with market needs. Throughout her career, Dr. Robinson has held pivotal roles at Thermo Electron Corporation and MedImmune Vaccines, and has served as an Entrepreneur in Residence at Blue Cross Blue Shield of Nebraska and the NIH SEED program. As a trusted advisor to startups, she offers strategic guidance on product development, payer engagement, and market access, with a steadfast commitment to clinical relevance, patient safety, and ethical rigor. She holds an MD from the University of Kansas School of Medicine, an MBA in Health Administration from the University of Colorado–Denver, and a Certificate in Venture Capital Finance from UC Berkeley School of Law. Dr. Robinson’s interdisciplinary expertise positions her at the forefront of healthcare innovation, driving growth and impact in a rapidly evolving landscape.

Dr. Ethel Rubin comes to us with a history of accomplishments in the medical device, corporate ventures and translational medicine industry. Most recently, Dr. Rubin oversaw global investments in commercially strategic studies for Medtronic's catheter ablation business, following leadership roles in clinical strategy and medical affairs for Medtronic CRDM. She has consulted for VCs and other corporate clients, taking the lead on due diligence for investment and M&A efforts through her consulting firm, Innovative BioStrategies, LLC. Ethel was previously Chief Scientific Officer of two Maryland companies, CSA Medical, Inc. and BioFortis, Inc, where she played a key role in technology development and commercialization efforts. A cell and molecular scientist by training, Dr. Rubin's research at The Johns Hopkins School of Medicine Sidney Kimmel Comprehensive Cancer Center elucidated pathways for potential intervention in breast cancer. She earned a PhD in Biochemistry and Biophysics from the University of Rochester School of Medicine and Dentistry and has held business leadership roles in many organizations, including Women In Bio, MIDC, GBTC BioTech Roundtable and the Emerging Technology Center incubator, among others.

Mona earned her doctorate in Biochemistry from Virginia Commonwealth University and her MBA from George Mason University. With over eight years of experience as a consultant in the business and science sectors, Mona brings a unique blend of scientific expertise and business acumen to her role at BioHealth Innovation. She specializes in entrepreneurship, innovation, strategy, and marketing, assisting companies in developing comprehensive marketing strategies, product launch plans, and development strategies. Mona diverse background enables her to help clients transform their scientific innovations into marketable products and services in the competitive life sciences landscape.

John Sullivan is a proven leader in healthcare innovation with extensive experience building, operating, and acquiring market-leading businesses that leverage technology to improve health outcomes, drive operational efficiencies, and reduce healthcare costs. Throughout his career, he has demonstrated exceptional ability to work closely with customers, understand complex market needs, and develop products and services designed for rapid marketplace adoption. His comprehensive background spans multiple healthcare sectors including medical devices, biotechnology, healthcare IT, digital health, consumer health, pharmacy, and supply chain management.

Susan Solinsky is an Entrepreneur in Residence at BHI, where she leverages her expertise in commercialization, go-to-market strategy, and fundraising to help healthcare organizations successfully navigate market entry. With a track record of scaling technology-driven healthcare startups, Susan specializes in revenue growth, payer and provider relationships, operational efficiency, and building world-class teams. Her leadership has propelled companies from early-stage development to over $120 million in revenue, particularly ones pioneering new care models. She is passionate about harnessing AI, machine learning, and innovative health technologies to expand access, improve outcomes, and drive systemic change—especially in behavioral and women’s health. As a Strategic Operator with Kayne Anderson and Composition Capital, Susan supports the growth and innovation of healthcare-focused portfolio companies. She serves on the boards of TeleMed2U, Carium, and MDisrupt, organizations advancing virtual care and healthtech validation, and advises women’s health startups, including LunaJoy and Lovu. Previously, Susan was Co-Founder of Ellipsis Health (Series A+), where she played a pivotal role in commercializing AI-powered voice technology that established a clinically validated vital sign for mental health. She also led enterprise sales at Phreesia (IPO 2019) and co-founded Vital Score, a behavioral health technology company acquired by Phreesia. Her experience includes serving as Managing Partner at Reditus Revenue Solutions, scaling revenue cycle strategies, and holding key leadership roles as part of the founding team at The Advisory Board Company (IPO) and The Corporate Executive Board (IPO). A champion for female entrepreneurs, Susan has directed the Women’s Health Tech Initiative at HITLAB for five years, connecting startups with funders and industry leaders to drive innovation. She is a founding LP of the How Women Invest Fund, an investor in venture funds such as Swizzle Ventures, Emmeline Ventures, Scrub Capital, and DigitalDx, and also an angel investor in women-led healthcare disruptors, including Avanlee Care, Gabbi, C-Plan.ai and MDisrupt. Recognized as one of Becker’s Hospital Review’s “Women in Health IT to Know” for the past four years, Susan frequently speaks at industry events and serves on the board of Synapse School, fostering the next generation of changemakers. She holds an A.B. from Princeton University and remains committed to advancing healthcare, technology, and education through leadership and innovation.

Michael J. Thomas is a distinguished healthcare executive and venture capital investor with over three decades of experience achieving remarkable successes in strategic and corporate venture capital investments, turnarounds, IPOs, startup operations, and commercialization of innovative healthcare products and services. As an operating executive, he has achieved investor returns ranging from 3x to 80x, establishing himself as a proven value creator in the healthcare technology sector. Michael earned his Bachelor's Degree in Microbiology from Cornell University in 1989, where he was a varsity baseball player and served as House Manager for the Phi Kappa Psi fraternity. His career began in pharmaceutical sales at Merck & Co. (1989-1992) and Glaxo Inc. (now GlaxoSmithKline, 1992-1995), where he demonstrated exceptional performance, earning President's Club Awards and transforming underperforming territories into top revenue generators.